ANIP
ANI Pharmaceuticals, Inc.
Price Chart
Latest Quote
$81.11
+1.91 (+2.41%)
Current Price
| Previous Close | $79.20 |
| Open | $79.77 |
| Day High | $81.28 |
| Day Low | $79.25 |
| Volume | 338,031 |
Stock Information
| Shares Outstanding | 22.73M |
| Total Debt | $630.21M |
| Cash Equivalents | $326.06M |
| Revenue | $923.71M |
| Net Income | $83.94M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $1.84B |
| P/E Ratio | 20.74 |
| EPS (TTM) | $3.91 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.02B |
| Sales | $923.71M |
| Income | $83.94M |
| Book/sh | $26.34 |
| Cash/sh | $14.34 |
| Employees | 970 |
Financial Ratios
| Quick Ratio | 2.43 |
| Current Ratio | 3.12 |
| Debt/Eq | 112.08 |
| EPS Growth TTM | 88.10% |
Returns & Margins
| ROA | 4.97% |
| ROE | 18.32% |
| Gross Margin | 60.83% |
| Operating Margin | 16.30% |
| Profit Margin | 9.98% |
Ownership
| Insider Ownership | 6.89% |
| Institutional Ownership | 110.38% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 7.64 |
| P/S | 2.00 |
| P/B | 3.08 |
Analyst Data
| Recommendation | none |
| Target Price | $109.88 |
Technical Indicators
| SMA20 | $79.77 |
| SMA50 | $79.17 |
| SMA200 | $83.53 |
| RSI | 57.73 |
| ATR | 2.5750 |
| Shares Float | 19.46M |
| Short Float | 19.44% |
| Short Ratio | 9.79 |
| Volatility | 0.44 |
| Rel Volume | 0.79 |
Performance History
| Week | +3.31% |
| Month | -3.51% |
| Quarter | +9.55% |
| 6 Months | -1.89% |
| YTD | +3.42% |
| Year | +33.25% |
| 3 Years | +79.69% |
| 5 Years | +136.13% |
| 10 Years | +45.46% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $81.11 | 338,200 |
| 2026-06-04 | $79.20 | 548,900 |
| 2026-06-03 | $75.23 | 257,500 |
| 2026-06-02 | $74.65 | 264,500 |
| 2026-06-01 | $76.71 | 427,900 |
| 2026-05-29 | $78.51 | 430,000 |
| 2026-05-28 | $81.11 | 174,100 |
| 2026-05-27 | $81.76 | 335,300 |
| 2026-05-26 | $81.41 | 456,100 |
| 2026-05-22 | $82.72 | 562,400 |
| 2026-05-21 | $82.77 | 324,100 |
| 2026-05-20 | $82.00 | 345,600 |
| 2026-05-19 | $80.32 | 257,500 |
| 2026-05-18 | $79.34 | 169,200 |
| 2026-05-15 | $78.01 | 325,000 |
| 2026-05-14 | $79.58 | 223,800 |
| 2026-05-13 | $80.88 | 308,800 |
| 2026-05-12 | $79.50 | 561,900 |
| 2026-05-11 | $78.71 | 895,800 |
| 2026-05-08 | $81.86 | 1,307,700 |
| 2026-05-07 | $83.91 | 400,500 |
| 2026-05-06 | $84.06 | 269,300 |
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
đ° Latest News
How ANIâs Estradiol Gel Recall at ANI Pharmaceuticals (ANIP) Has Changed Its Quality-Control Investment Story
Simply Wall St. âĸ 2026-06-05T09:08:57Z
Ani (ANIP) Q1 2026 Earnings Call Transcript
Motley Fool âĸ 2026-06-01T17:25:09Z
2 Growth Stocks with Explosive Upside and 1 We Avoid
StockStory âĸ 2026-05-29T19:20:38Z
Q1 Earnings Outperformers: ANI Pharmaceuticals (NASDAQ:ANIP) And The Rest Of The Pharmaceuticals Stocks
StockStory âĸ 2026-05-21T01:32:55Z
ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem
Simply Wall St. âĸ 2026-05-19T18:50:04Z
2 Profitable Stocks with Competitive Advantages and 1 Facing Headwinds
StockStory âĸ 2026-05-18T07:16:55Z
How Raised 2026 Guidance And A New Buyback At ANI Pharmaceuticals (ANIP) Has Changed Its Investment Story
Simply Wall St. âĸ 2026-05-17T15:12:11Z
ANI Pharmaceuticals Refocuses On Rare Disease As Buybacks And Insider Sales Rise
Simply Wall St. âĸ 2026-05-17T02:06:48Z
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
Zacks âĸ 2026-05-15T15:46:00Z
Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million
Motley Fool âĸ 2026-05-11T21:29:29Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $341,310,000 | $250,210,000 | $181,513,000 | $136,104,000 |
| Cost Of Revenue | $341,310,000 | $250,210,000 | $181,513,000 | $138,785,000 |
| Total Revenue | $883,366,000 | $614,376,000 | $486,816,000 | $316,385,000 |
| Operating Revenue | $883,366,000 | $614,376,000 | $486,816,000 | $316,385,000 |
| Expenses | ||||
| Interest Expense | $20,060,000 | $17,602,000 | $26,940,000 | $28,052,000 |
| Total Expenses | $802,136,000 | $612,158,000 | $437,287,000 | $342,119,000 |
| Other Income Expense | $34,621,000 | $-6,828,000 | $-2,717,000 | $-8,879,000 |
| Other Non Operating Income Expenses | $1,934,000 | $-4,033,000 | $-159,000 | $670,000 |
| Net Non Operating Interest Income Expense | $-20,060,000 | $-17,602,000 | $-26,940,000 | $-28,052,000 |
| Interest Expense Non Operating | $20,060,000 | $17,602,000 | $26,940,000 | $28,052,000 |
| Operating Expense | $460,826,000 | $361,948,000 | $255,774,000 | $203,334,000 |
| Other Operating Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $78,337,000 | $-18,522,000 | $18,779,000 | $-47,896,000 |
| Net Interest Income | $-20,060,000 | $-17,602,000 | $-26,940,000 | $-28,052,000 |
| Normalized Income | $51,599,034 | $-16,190,970 | $21,196,310 | $-40,600,564 |
| Net Income From Continuing And Discontinued Operation | $78,337,000 | $-18,522,000 | $18,779,000 | $-47,896,000 |
| Total Operating Income As Reported | $111,093,000 | $584,000 | $46,971,000 | $-35,283,000 |
| Average Dilution Earnings | $352,000 | $0 | $16,000 | - |
| Net Income Common Stockholders | $70,217,000 | $-20,147,000 | $15,475,000 | $-49,521,000 |
| Net Income | $78,337,000 | $-18,522,000 | $18,779,000 | $-47,896,000 |
| Net Income Including Noncontrolling Interests | $78,337,000 | $-18,522,000 | $18,779,000 | $-47,896,000 |
| Net Income Continuous Operations | $78,337,000 | $-18,522,000 | $18,779,000 | $-47,896,000 |
| Pretax Income | $95,791,000 | $-22,212,000 | $19,872,000 | $-62,665,000 |
| Special Income Charges | $29,863,000 | $-9,102,000 | $-2,558,000 | $-9,549,000 |
| Operating Income | $81,230,000 | $2,218,000 | $49,529,000 | $-25,734,000 |
| Depreciation Amortization Depletion Income Statement | $91,417,000 | $67,731,000 | $59,791,000 | $56,972,000 |
| Depreciation And Amortization In Income Statement | $91,417,000 | $67,731,000 | $59,791,000 | $56,972,000 |
| Gross Profit | $542,056,000 | $364,166,000 | $305,303,000 | $177,600,000 |
| Per Share | ||||
| Diluted EPS | $3.32 | $-1.04 | $0.85 | $-3.05 |
| Basic EPS | $3.50 | $-1.04 | $0.86 | $-3.05 |
| Other | ||||
| Tax Effect Of Unusual Items | $5,949,034 | $-463,970 | $-140,690 | $-2,253,564 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $174,581,000 | $65,916,000 | $109,161,000 | $34,589,000 |
| Total Unusual Items | $32,687,000 | $-2,795,000 | $-2,558,000 | $-9,549,000 |
| Total Unusual Items Excluding Goodwill | $32,687,000 | $-2,795,000 | $-2,558,000 | $-9,549,000 |
| Reconciled Depreciation | $91,417,000 | $67,731,000 | $59,791,000 | $59,653,000 |
| EBITDA (Bullshit earnings) | $207,268,000 | $63,121,000 | $106,603,000 | $25,040,000 |
| EBIT | $115,851,000 | $-4,610,000 | $46,812,000 | $-34,613,000 |
| Diluted Average Shares | $21,228,000 | $19,318,000 | $18,194,000 | $16,260,000 |
| Basic Average Shares | $20,053,000 | $19,318,000 | $18,001,000 | $16,260,000 |
| Diluted NI Availto Com Stockholders | $70,569,000 | $-20,147,000 | $15,491,000 | $-49,521,000 |
| Otherunder Preferred Stock Dividend | $6,963,000 | $0 | $1,679,000 | - |
| Preferred Stock Dividends | $1,157,000 | $1,625,000 | $1,625,000 | $1,625,000 |
| Tax Provision | $17,454,000 | $-3,690,000 | $1,093,000 | $-14,769,000 |
| Gain On Sale Of Ppe | $-382,000 | $5,347,000 | $0 | $0 |
| Impairment Of Capital Assets | $767,000 | $7,600,000 | $0 | $112,000 |
| Restructuring And Mergern Acquisition | $-31,012,000 | $-619,000 | $2,558,000 | $9,437,000 |
| Gain On Sale Of Security | $2,824,000 | $6,307,000 | - | - |
| Research And Development | $51,664,000 | $44,581,000 | $34,286,000 | $22,318,000 |
| Selling General And Administration | $317,745,000 | $249,636,000 | $161,697,000 | $124,044,000 |
| Other Special Charges | - | $7,468,000 | - | - |
Fetched: 2026-06-06
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,282,000 | $-173,294,000 | $220,369,000 | $58,684,000 |
| Total Assets | $1,440,377,000 | $1,284,469,000 | $904,422,000 | $760,087,000 |
| Total Non Current Assets | $687,260,000 | $756,013,000 | $384,606,000 | $415,826,000 |
| Non Current Deferred Assets | $69,072,000 | $85,106,000 | $90,711,000 | $81,363,000 |
| Non Current Deferred Taxes Assets | $69,072,000 | $85,106,000 | $90,711,000 | $81,363,000 |
| Financial Assets | $13,706,000 | $12,220,000 | $12,072,000 | $11,361,000 |
| Goodwill And Other Intangible Assets | $542,006,000 | $601,824,000 | $237,230,000 | $279,856,000 |
| Other Intangible Assets | $479,526,000 | $541,834,000 | $209,009,000 | $251,635,000 |
| Current Assets | $753,117,000 | $528,456,000 | $519,816,000 | $344,261,000 |
| Other Current Assets | $23,189,000 | $17,975,000 | $17,400,000 | $8,387,000 |
| Restricted Cash | $36,000 | $33,000 | $0 | $5,006,000 |
| Prepaid Assets | $11,027,000 | $772,000 | $0 | $3,827,000 |
| Inventory | $143,067,000 | $136,782,000 | $111,196,000 | $105,355,000 |
| Receivables | $281,082,000 | $221,726,000 | $162,079,000 | $165,438,000 |
| Accounts Receivable | $281,082,000 | $221,726,000 | $162,079,000 | $165,438,000 |
| Allowance For Doubtful Accounts Receivable | $-171,803,000 | $-127,824,000 | $-97,262,000 | $-161,052,000 |
| Gross Accounts Receivable | $452,885,000 | $349,550,000 | $259,341,000 | $326,490,000 |
| Cash Cash Equivalents And Short Term Investments | $294,716,000 | $151,168,000 | $221,121,000 | $48,228,000 |
| Cash And Cash Equivalents | $285,585,000 | $144,861,000 | $221,121,000 | $48,228,000 |
| Assets Held For Sale Current | - | $0 | $8,020,000 | $8,020,000 |
| Other Non Current Assets | - | - | - | $11,361,000 |
| Debt | ||||
| Net Debt | $331,450,000 | $479,231,000 | $64,548,000 | $238,291,000 |
| Total Debt | $617,035,000 | $624,092,000 | $285,669,000 | $286,519,000 |
| Long Term Debt And Capital Lease Obligation | $599,767,000 | $614,920,000 | $284,819,000 | $285,669,000 |
| Long Term Debt | $599,767,000 | $614,920,000 | $284,819,000 | $285,669,000 |
| Current Debt And Capital Lease Obligation | $17,268,000 | $9,172,000 | $850,000 | $850,000 |
| Current Debt | $17,268,000 | $9,172,000 | $850,000 | $850,000 |
| Other Current Borrowings | $17,268,000 | $9,172,000 | $850,000 | $850,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $899,653,000 | $855,939,000 | $446,823,000 | $421,547,000 |
| Total Non Current Liabilities Net Minority Interest | $621,541,000 | $661,487,000 | $301,346,000 | $322,108,000 |
| Other Non Current Liabilities | $21,774,000 | $25,606,000 | $16,527,000 | $36,439,000 |
| Current Liabilities | $278,112,000 | $194,452,000 | $145,477,000 | $99,439,000 |
| Other Current Liabilities | $167,000 | $29,000 | $12,266,000 | - |
| Payables And Accrued Expenses | $173,276,000 | $108,252,000 | $78,897,000 | $54,878,000 |
| Payables | $64,822,000 | $53,177,000 | $44,847,000 | $29,305,000 |
| Total Tax Payable | $2,239,000 | $7,521,000 | $8,164,000 | $0 |
| Income Tax Payable | $2,239,000 | $7,521,000 | $8,164,000 | $0 |
| Accounts Payable | $62,583,000 | $45,656,000 | $36,683,000 | $29,305,000 |
| Derivative Product Liabilities | - | - | - | - |
| Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $540,724,000 | $403,680,000 | $432,749,000 | $313,690,000 |
| Total Equity Gross Minority Interest | $540,724,000 | $428,530,000 | $457,599,000 | $338,540,000 |
| Stockholders Equity | $540,724,000 | $428,530,000 | $457,599,000 | $338,540,000 |
| Gains Losses Not Affecting Retained Earnings | $1,033,000 | $5,344,000 | $8,857,000 | $12,168,000 |
| Other Equity Adjustments | $1,033,000 | $5,344,000 | $8,857,000 | $12,168,000 |
| Retained Earnings | $-23,099,000 | $-100,279,000 | $-80,132,000 | $-97,286,000 |
| Preferred Stock Equity | - | $24,850,000 | $24,850,000 | $24,850,000 |
| Other | ||||
| Treasury Shares Number | $621,296 | $429,555 | $263,943 | $149,031 |
| Ordinary Shares Number | $22,491,281 | $21,108,152 | $20,466,953 | $17,494,466 |
| Share Issued | $23,112,577 | $21,537,707 | $20,730,896 | $17,643,497 |
| Tangible Book Value | $-1,282,000 | $-198,144,000 | $195,519,000 | $33,834,000 |
| Invested Capital | $1,157,759,000 | $1,027,772,000 | $718,418,000 | $600,209,000 |
| Working Capital | $475,005,000 | $334,004,000 | $374,339,000 | $244,822,000 |
| Total Capitalization | $1,140,491,000 | $1,043,450,000 | $742,418,000 | $624,209,000 |
| Treasury Stock | $33,249,000 | $21,040,000 | $10,081,000 | $5,094,000 |
| Additional Paid In Capital | $596,036,000 | $519,653,000 | $514,103,000 | $403,901,000 |
| Capital Stock | $3,000 | $24,852,000 | $24,852,000 | $24,851,000 |
| Common Stock | $3,000 | $2,000 | $2,000 | $1,000 |
| Preferred Stock | $0 | $24,850,000 | $24,850,000 | $24,850,000 |
| Non Current Accrued Expenses | $0 | $20,961,000 | $0 | - |
| Pensionand Other Post Retirement Benefit Plans Current | $37,897,000 | $37,725,000 | $23,786,000 | $10,312,000 |
| Current Provisions | $49,504,000 | $39,274,000 | $29,678,000 | $33,399,000 |
| Current Accrued Expenses | $108,454,000 | $55,075,000 | $34,050,000 | $25,573,000 |
| Goodwill | $62,480,000 | $59,990,000 | $28,221,000 | $28,221,000 |
| Net PPE | $62,476,000 | $56,863,000 | $44,593,000 | $43,246,000 |
| Accumulated Depreciation | $-52,690,000 | $-44,880,000 | $-32,935,000 | $-32,712,000 |
| Gross PPE | $115,166,000 | $101,743,000 | $77,528,000 | $75,958,000 |
| Leases | $1,405,000 | $1,297,000 | $0 | - |
| Construction In Progress | $8,825,000 | $4,568,000 | $7,692,000 | $4,604,000 |
| Other Properties | $650,000 | $1,161,000 | - | - |
| Machinery Furniture Equipment | $76,043,000 | $68,697,000 | $50,412,000 | $53,146,000 |
| Buildings And Improvements | $25,833,000 | $24,438,000 | $17,875,000 | $16,659,000 |
| Land And Improvements | $2,410,000 | $1,582,000 | $1,549,000 | $1,549,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Inventories | $9,743,000 | $9,977,000 | $9,617,000 | $7,720,000 |
| Finished Goods | $55,988,000 | $57,966,000 | $36,198,000 | $28,020,000 |
| Work In Process | $2,973,000 | $1,665,000 | $3,144,000 | $1,889,000 |
| Raw Materials | $74,363,000 | $67,174,000 | $62,237,000 | $67,726,000 |
| Other Short Term Investments | $9,131,000 | $6,307,000 | $0 | - |
| Preferred Shares Number | - | $25,000 | $25,000 | $25,000 |
| Inventories Adjustments Allowances | - | - | - | $-10,278,000 |
| Current Deferred Revenue | - | - | - | - |
Fetched: 2026-06-06
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $150,904,000 | $47,064,000 | $100,448,000 | $-47,658,000 |
| Operating Activities | ||||
| Operating Cash Flow | $185,225,000 | $64,017,000 | $118,959,000 | $-31,203,000 |
| Cash Flow From Continuing Operating Activities | $185,225,000 | $64,017,000 | $118,959,000 | $-31,203,000 |
| Operating Gains Losses | $382,000 | $2,121,000 | - | $-750,000 |
| Investing Activities | ||||
| Capital Expenditure | $-34,321,000 | $-16,953,000 | $-18,511,000 | $-16,455,000 |
| Investing Cash Flow | $-34,321,000 | $-404,719,000 | $-18,511,000 | $-15,738,000 |
| Cash Flow From Continuing Investing Activities | $-34,321,000 | $-404,719,000 | $-18,511,000 | $-15,738,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-12,209,000 | $-10,959,000 | $-4,987,000 | $-1,959,000 |
| Issuance Of Capital Stock | $0 | $0 | $80,555,000 | $0 |
| Financing Cash Flow | $-9,944,000 | $264,945,000 | $67,439,000 | $-5,126,000 |
| Cash Flow From Continuing Financing Activities | $-9,944,000 | $264,945,000 | $67,439,000 | $-5,126,000 |
| Net Other Financing Charges | $-26,000 | $-74,178,000 | $-12,500,000 | - |
| Cash Dividends Paid | $-1,157,000 | $-1,625,000 | $-1,625,000 | $-1,625,000 |
| Preferred Stock Dividend Paid | $-1,157,000 | $-1,625,000 | $-1,625,000 | $-1,625,000 |
| Net Common Stock Issuance | $-12,209,000 | $-10,959,000 | $75,568,000 | $-1,959,000 |
| Common Stock Issuance | $0 | $0 | $80,555,000 | $0 |
| Net Preferred Stock Issuance | - | - | $0 | $0 |
| Preferred Stock Issuance | - | - | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-10,156,000 | $-296,031,000 | $-3,000,000 | $-3,000,000 |
| Issuance Of Debt | $0 | $641,250,000 | $0 | $0 |
| Interest Paid Supplemental Data | $26,929,000 | $24,379,000 | $31,431,000 | $21,477,000 |
| Income Tax Paid Supplemental Data | $17,674,000 | $19,061,000 | $1,228,000 | $288,000 |
| End Cash Position | $285,621,000 | $144,894,000 | $221,121,000 | $53,234,000 |
| Beginning Cash Position | $144,894,000 | $221,121,000 | $53,234,000 | $105,301,000 |
| Effect Of Exchange Rate Changes | $-233,000 | $-470,000 | $0 | $0 |
| Changes In Cash | $140,960,000 | $-75,757,000 | $167,887,000 | $-52,067,000 |
| Proceeds From Stock Option Exercised | $13,604,000 | $6,488,000 | $8,996,000 | $1,458,000 |
| Common Stock Payments | $-12,209,000 | $-10,959,000 | $-4,987,000 | $-1,959,000 |
| Net Issuance Payments Of Debt | $-10,156,000 | $345,219,000 | $-3,000,000 | $-3,000,000 |
| Net Long Term Debt Issuance | $-10,156,000 | $345,219,000 | $-3,000,000 | $-3,000,000 |
| Long Term Debt Payments | $-10,156,000 | $-296,031,000 | $-3,000,000 | $-3,000,000 |
| Long Term Debt Issuance | $0 | $641,250,000 | $0 | $0 |
| Net Business Purchase And Sale | $0 | $-401,280,000 | $0 | $-33,000 |
| Purchase Of Business | $0 | $-401,280,000 | $0 | $-33,000 |
| Net Intangibles Purchase And Sale | $-20,486,000 | $-717,000 | $-9,643,000 | $-7,579,000 |
| Purchase Of Intangibles | $-20,486,000 | $-717,000 | $-9,643,000 | $-7,579,000 |
| Net PPE Purchase And Sale | $-13,835,000 | $-2,722,000 | $-8,868,000 | $-8,126,000 |
| Sale Of PPE | $0 | $13,514,000 | $0 | $750,000 |
| Purchase Of PPE | $-13,835,000 | $-16,236,000 | $-8,868,000 | $-8,876,000 |
| Change In Working Capital | $-7,123,000 | $-11,185,000 | $24,860,000 | $-51,300,000 |
| Change In Other Working Capital | $-5,302,000 | $7,687,000 | $8,269,000 | $-2,399,000 |
| Change In Payables And Accrued Expense | $67,694,000 | $21,373,000 | $28,088,000 | $12,435,000 |
| Change In Accrued Expense | $52,538,000 | $20,894,000 | $20,536,000 | $7,557,000 |
| Change In Payable | $15,156,000 | $479,000 | $7,552,000 | $4,878,000 |
| Change In Account Payable | $15,156,000 | $479,000 | $7,552,000 | $5,038,000 |
| Change In Prepaid Assets | $-5,024,000 | $2,129,000 | $-9,015,000 | $-798,000 |
| Change In Inventory | $-5,961,000 | $-21,287,000 | $-5,841,000 | $-23,626,000 |
| Change In Receivables | $-58,530,000 | $-21,087,000 | $3,359,000 | $-36,912,000 |
| Changes In Account Receivables | $-58,530,000 | $-21,087,000 | $3,359,000 | $-36,912,000 |
| Other Non Cash Items | $-27,897,000 | $15,148,000 | $6,617,000 | $9,170,000 |
| Stock Based Compensation | $37,929,000 | $29,344,000 | $20,652,000 | $14,599,000 |
| Unrealized Gain Loss On Investment Securities | $-2,824,000 | $-6,307,000 | $0 | $0 |
| Asset Impairment Charge | $767,000 | $7,600,000 | $0 | $574,000 |
| Deferred Tax | $14,237,000 | $-21,913,000 | $-11,740,000 | $-15,253,000 |
| Deferred Income Tax | $14,237,000 | $-21,913,000 | $-11,740,000 | $-15,253,000 |
| Depreciation Amortization Depletion | $91,417,000 | $67,731,000 | $59,791,000 | $59,653,000 |
| Depreciation And Amortization | $91,417,000 | $67,731,000 | $59,791,000 | $59,653,000 |
| Net Income From Continuing Operations | $78,337,000 | $-18,522,000 | $18,779,000 | $-47,896,000 |
| Change In Tax Payable | - | $-1,415,000 | $11,991,000 | $-160,000 |
| Change In Income Tax Payable | - | $-1,415,000 | $11,991,000 | $-160,000 |
| Gain Loss On Sale Of PPE | - | $-5,347,000 | $0 | $-750,000 |
| Net Short Term Debt Issuance | - | - | $0 | $0 |
| Short Term Debt Issuance | - | - | $0 | $0 |
| Short Term Debt Payments | - | - | - | - |
Fetched: 2026-06-06